ConCallIQ
Go Pro
Home › Alivus Life Sciences › Revenue History

Alivus Life Sciences Revenue History — Quarter by Quarter

Alivus Life Sciences's revenue moved from ₹588 Cr in Q2 FY26 to ₹689 Cr in Q4 FY26, a 17.2% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q4 FY26₹689 Cr+6.11%
Q3 FY26₹673 Cr+4.8%
Q2 FY26₹588 Cr+16%

What management said about revenue

G

Q4 FY26 · Two new CDMO deals expected in early H2 FY27

Management expects to close two new CDMO deals in the early second half of FY27, continuing momentum.

G

Q3 FY26 · Revenue growth: high single-digit for FY26

Management expects high single-digit revenue growth for FY26, driven by non-GPL segment and CDMO ramp-up.

G

Q3 FY26 · CDMO: 1-2 new projects expected by Q1 FY27

Management expects to conclude 1-2 new CDMO projects by Q1 FY27, with early quantities already supplied.

G

Q2 FY26 · High single-digit revenue growth for FY26

Management reaffirmed guidance of high single-digit revenue growth for FY26, driven by stronger H2 performance from non-GPL business, GPL recovery, and CDMO ramp-up.

G

Q2 FY26 · CDMO turnaround in H2 FY26

Management expects a meaningful turnaround in CDMO performance in H2, driven by new project additions and ramp-up of existing projects.